文献速递MDS 与骨髓增殖性肿瘤

基于二代测序技术分析基因突变对芦可替尼治疗骨髓纤维化患者疗效的影响

[Analysis of the effect of gene mutations on the efficacy of ruxolitinib in patients with myelofibrosis based on second-generation sequencing technology].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2022-01-01

该研究回顾性分析2017年7月至2020年12月接受芦可替尼治疗的56例骨髓纤维化(MF)患者的临床资料,采用二代测序技术检测127个血液肿瘤相关基因突变,分析突变基因与芦可替尼疗效的关系。结果显示,MF患者携带的基因突变类型、数量以及高危基因突变(HMR)对芦可替尼疗效有一定影响。

要点

  • 56例MF患者中50例(89.29%)携带驱动基因突变,22例(39.29%)携带≥3个基因突变,29例(51.79%)检出高危基因突变(HMR)。
  • 携带≥3个突变患者芦可替尼改善体质性症状及缩脾仍较好(P=0.001,P<0.001),但TTF及PFS明显缩短(P=0.007,P=0.042)。
  • 携带≥2个HMR患者缩脾效果较差(t=10.471,P=0.034),TTF及PFS明显缩短(P<0.001,P=0.001)。

核心结论

  • MF患者携带的基因突变类型、数量以及HMR对芦可替尼疗效有一定影响。

研究设计与样本

  • 回顾性分析2017年7月至2020年12月服用芦可替尼治疗并应用二代测序技术检测127个血液肿瘤相关基因突变的56例MF患者的临床资料。

主要发现

  • 56例患者中,原发性骨髓纤维化(PMF)36例、真性红细胞增多症(PV)后骨髓纤维化(PPV-MF)9例、原发性血小板增多症(ET)后骨髓纤维化(PET-MF)11例。
  • 50例(89.29%)携带驱动基因突变,22例(39.29%)携带基因突变≥3个,29例(51.79%)检出高危基因突变(HMR)。
  • 对于基因突变≥3个的MF患者,芦可替尼仍有较好的改善体质性症状及缩小脾脏的效果(P=0.001,P<0.001)。
  • 与基因突变<3个组比较,基因突变≥3个组TTF及PFS明显缩短[356(55~1061)d对471.5(50~1270)d,z=-2.701,P=0.007;444(91~4109)d对1248.5(91~7061)d,z=-2.030,P=0.042]。
  • 与未检出HMR的患者比较,≥2个HMR患者的芦可替尼缩脾效果较差(t=10.471,P=0.034),TTF及PFS明显缩短(P<0.001,P=0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To assess the effect of gene mutations on the efficacy of ruxolitinib for treating myelofibrosis (MF) . Methods: We retrospectively analyzed the clinical data of 56 patients with MF treated with ruxolitinib from July 2017 to December 2020 and applied second-generation sequencing (NGS) technology to detect 127 hematologic tumor-related gene mutations. Additionally, we analyzed the relationship between mutated genes and the efficacy of ruxolitinib. Results: ①Among the 56 patients, there were 36 cases of primary bone marrow fibrosis (PMF) , 9 cases of bone marrow fibrosis (ppv-mf) after polycythemia vera, and 11 cases of bone marrow fibrosis (PET-MF) after primary thrombocytosis (ET) . ②Fifty-six patients with MF taking ruxolitinib underwent NGS, among whom, 50 (89.29%) carried driver mutations, 22 (39.29%) carried ≥3 mutations, and 29 (51.79%) carried high-risk mutations (HMR) . ③ For patients with MF carrying ≥ 3 mutations, ruxolitinib still had a better effect of improving somatic symptoms and shrinking the spleen (P=0.001, P<0.001) , but TTF and PFS were significantly shorter in patients carrying ≥ 3 mutations (P=0.007, P=0.042) . ④For patients carrying ≥ 2 HMR mutations, ruxolitinib was less effective in shrinking the spleen than in those who did not carry HMR (t= 10.471, P=0.034) , and the TTF and PFS were significantly shorter in patients carrying ≥2 HMR mutations (P<0.001, P=0.001) . ⑤Ruxolitinib had poorer effects on spleen reduction, symptom improvement, and stabilization of myelofibrosis in patients carrying additional mutations in ASXL1, EZH2, and SRSF2. Moreover, patients carrying ASXL1 and EZH2 mutations had significantly shorter TTF [ASXL1: 360 (55-1270) d vs 440 (55-1268) d, z=-3.115, P=0.002; EZH2: 327 (55-975) d vs 404 (50-1270) d, z=-3.219, P=0.001], and significantly shorter PFS compared to non-carriers [ASXL1: 457 (50-1331) d vs 574 (55-1437) d, z=-3.219, P=0.001) ; 428 (55-1331) d vs 505 (55-1437) d, z=-2.576, P=0.008]. Conclusion: The type and number of mutations carried by patients with myelofibrosis and HMR impact the efficacy of ruxolitinib. 目的: 评估基因突变对芦可替尼治疗骨髓纤维化(MF)疗效的影响。 方法: 回顾性分析2017年7月至2020年12月服用芦可替尼治疗并应用二代测序技术检测127个血液肿瘤相关基因突变的56例MF患者的临床资料,分析突变基因与芦可替尼疗效的关系。 结果: ①56例患者中,原发性骨髓纤维化(PMF)36例、真性红细胞增多症(PV)后骨髓纤维化(PPV-MF)9例,原发性血小板增多症(ET)后骨髓纤维化(PET-MF)11例。②50例(89.29%)携带驱动基因突变,22例(39.29%)携带基因突变≥3个,29例(51.79%)检出高危基因突变(HMR)。③对于基因突变≥3个的MF患者,芦可替尼仍有较好的改善体质性症状及缩小脾脏的效果(P=0.001,P<0.001)。与基因突变<3个组比较,基因突变≥3个组停药前持续用药时间(TTF)及无进展生存期(PFS)明显缩短[356(55~1061)d对471.5(50~1270)d,z=-2.701,P=0.007;444(91~4109)d对1248.5(91~7061)d,z=-2.030,P=0.042]。④与未检出HMR的患者比较,≥2个HMR患者的芦可替尼缩脾效果较差(t=10.471,P=0.034),TTF及PFS明显缩短(P<0.001,P=0.001)。⑤在携带ASXL1、EZH2、SRSF2等附加基因突变患者中,芦可替尼缩脾、症状改善及稳定骨髓纤维化作用较差,携带ASXL1、EZH2突变患者TTF[ASXL1:360(55~1270)d对440(55~1268)d,z=-3.115,P=0.002;EZH2:327(55~975)d对404(50~1270)d,z=-3.219,P=0.001]及PFS较未携带者明显缩短(ASXL1:457(50~1331)d对574(55~1437)d,z=-3.219,P=0.001;EZH2:428(55~1331)d对505(55~1437)d,z=-2.576,P=0.008]。 结论: MF患者携带的基因突变类型、数量以及HMR对芦可替尼疗效有一定影响。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Tan YX, Luo J, Huang JX, et al. [Analysis of the effect of gene mutations on the efficacy of ruxolitinib in patients with myelofibrosis based on second-generation sequencing technology]. Zhonghua Xue Ye Xue Za Zhi. 2022. PMID: 35680632. doi:10.3760/cma.j.issn.0253-2727.2022.04.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。